Brookline Capital Management Weighs in on BioVie Q3 Earnings

BioVie Inc. (NASDAQ:BIVI) – Stock analysts at Brookline Capital Management issued their Q3 2025 earnings per share (EPS) estimates for shares of BioVie in a research note issued on Tuesday, March 18th. Brookline Capital Management analyst T. Bussian expects that the company will post earnings per share of ($0.32) for the quarter. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. Brookline Capital Management also issued estimates for BioVie’s Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($1.63) EPS.

BioVie (NASDAQ:BIVI) last released its earnings results on Tuesday, February 11th. The company reported ($0.46) EPS for the quarter.

BioVie Price Performance

BioVie stock opened at $1.15 on Friday. The company has a market cap of $21.22 million, a price-to-earnings ratio of -0.12 and a beta of 0.51. The firm has a 50-day moving average of $1.62 and a 200-day moving average of $2.13. BioVie has a one year low of $0.99 and a one year high of $7.50.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BIVI. Millennium Management LLC bought a new stake in shares of BioVie during the 4th quarter worth approximately $245,000. Geode Capital Management LLC raised its position in BioVie by 223.3% during the fourth quarter. Geode Capital Management LLC now owns 123,408 shares of the company’s stock worth $247,000 after acquiring an additional 85,234 shares in the last quarter. Drive Wealth Management LLC acquired a new stake in BioVie in the fourth quarter valued at $120,000. Bank of Montreal Can acquired a new position in shares of BioVie during the 4th quarter worth about $100,000. Finally, Sanders Morris Harris LLC bought a new stake in shares of BioVie in the 4th quarter valued at about $85,000. 4.59% of the stock is owned by institutional investors and hedge funds.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.